Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$83.61 USD

83.61
5,456,718

+0.57 (0.69%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $83.61 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Gilead's (GILD) Veklury Gets EC Nod for Use in Early COVID-19

Gilead's (GILD) Veklury can now be used in the EU at the early stages of COVID-19 to help prevent disease progression in high-risk patients.

Vir (VIR), Glaxo's Xevudy Wins EC Approval for COVID-19

Vir Biotechnology, Inc. (VIR) and partner GlaxoSmithKline obtain the European Commission's nod for Xevudy for the early treatment of COVID-19.

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $72.31, moving +1.54% from the previous trading session.

Merck's (MRK) HIV Studies on Islatravir Put on Clinical Hold

With the FDA's clinical hold, no new studies can be initiated on Merck's (MRK) islatravir. While six studies on islatravir have been placed on full clinical hold, seven have been put on partial clinical hold.

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $70.25, moving -0.07% from the previous trading session.

Merck (MRK) Pauses Enrolment in HIV-1 Prevention Studies

Merck (MRK) pauses enrolment for two phase III studies evaluating islatravir for pre-exposure prophylaxis of HIV-1 infection, following the recommendation of an external data monitoring committee.

Amazon's (AMZN) AWS Gets Selected by Gilead, Boosts Clientele

Amazon's (AMZN) AWS is chosen by Gilead Sciences as the preferred cloud provider.

The Zacks Analyst Blog Highlights: Accenture, Raytheon, Becton, Dickinson and Co, Boeing and Gilead Sciences

The Zacks Analyst Blog Highlights: Accenture, Raytheon, Becton, Dickinson and Co, Boeing and Gilead Sciences

Mark Vickery headshot

Top Analyst Reports for Accenture, Raytheon & Becton, Dickinson

Today's Research Daily features new research reports on 16 major stocks, including Accenture plc (ACN), Raytheon Technologies Corporation (RTX), and Becton, Dickinson, and Company (BDX).

Ligand's (LGND) Drug-Developing Technologies Holds Potential

Ligand's (LGND) Captisol technology is a key driver for its topline. The company plans to spin off another potential technology platform, OmniAb, into a separate company.

Gilead Sciences (GILD) Stock Gains 20% YTD: What Lies Ahead?

Gilead's (GILD) performance in the year has been pretty good on contribution from Veklury. The company is now focusing on its oncology business as the virology business faces challenges.

Biotech Stock Roundup: Drug Approvals for BMRN, Updates From BIIB, BMY, MRNA & More

Drug approvals for BioMarin (BMRN) and regulatory updates from Biogen (BIIB), among others, have been the biotech sector's few key highlights during the past week.

Gilead (GILD) Gets EU Nod for Breast Cancer Drug, Trodelvy

The European Commission grants marketing authorization to Gilead's (GILD) Trodelvy as a monotherapy for the second-line treatment of adults with metastatic triple-negative breast cancer.

Gilead (GILD) Files BLA for Bulevirtide for Hepatitis Delta Virus

Gilead (GILD) submits a biologics license application to the FDA for bulevirtide for the treatment of chronic hepatitis delta virus infection in adults with compensated liver disease.

Gilead (GILD) Exercises Options to Three Arcus Programs

Gilead (GILD) exercises options to Arcus' anti-TIGIT Program (domvanalimab and AB308), etrumadenant (A2a/A2b Adenosine Receptor Antagonist), and quemliclustat (small Molecule CD73 Inhibitor).

Gilead (GILD), Everest Medicine Report Phase II Cancer Study Data (Revised)

Gilead (GLD) and partner Everest Medicine report that the mid-stage study of sacituzumab govitecan for triple-negative breast cancer achieved its main goal.

Gilead (GILD), Everest Medicine Report Phase II Cancer Study Data

Gilead (GLD) and partner Everest Medicine report that the mid-stage study of sacituzumab govitecan for triple-negative breast cancer achieved its main goal.

Ligand (LGND) Beats on Q3 Earnings, Plans to Separate OmniAb

Ligand (LGND) reports encouraging third-quarter 2021 numbers by beating estimates on both counts.

Sweta Jaiswal, FRM headshot

How Are Biotech ETFs Reacting to These Q3 Earnings Releases?

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

FATE's Q3 Loss Narrower Than Expected, Pipeline in Focus

FATE reports a year-over-year wider loss on increased R&D expenses in the third quarter.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Smart Beta ETF report for IBB

Intercept (ICPT) Beats on Q3 Earnings & Sales, Ups View

Intercept (ICPT) posts a narrower loss in the third quarter and sales beat estimates.

Gilead (GILD) Q3 Earnings Beat on Increased Veklury Sales

Gilead (GILD) beats on sales and earnings in the third quarter. While the HIV business is affected by the pandemic and generics, Veklury maintains momentum.

Mark Vickery headshot

Markets Close at or Near Record Highs; Sales Misses for AAPL, AMZN, SBUX

Most of these economic metrics and earnings reports are a peek in the rearview mirror; the real news is ahead of us.

Gilead Sciences (GILD) Q3 Earnings and Revenues Surpass Estimates

Gilead (GILD) delivered earnings and revenue surprises of 54.07% and 19.16%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?